Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point

International Journal of Radiation Oncology Biology Physics

November 1, 2007

Dr. Yaparpalvi from New York City runs a dosimetric study that reveals advantages to Cesium prostate brachytherapy over brachytherapy with other available isotopes. Again, the homogeneity of dose and the very low rate of “hot spots” are highly attractive from a dosimetric point of view.

“Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point Yaparpalvi, R. et al. International Journal of Radiation Oncology • Biology • Physics , Volume 69 , Issue 3 , S677 – S678”

Related posts

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer

Authors: Amar U. Kishan, MD; Ryan R. Cook, MSPH; Jay P. Ciezki, MD; et al

Clinical Outcomes of a Phase II, Multi-Institutional Cesium-131 Premanent Prostate Brachytherapy Trial

Authors: B. Prestidge

Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy

Authors: J.S. Musmacher, R.T. Byrnes, M. Ghaly, K. Satchwill, L. Rumpf

IPSS trends for Cs-131 permanent prostate brachytherapy

Authors: Andrew Jones, Ph.D., Jared Treas, M.S., John Danella, M.D., Omar Yumen, M.D.

Company

Brachytherapy

Theranostics

Newsletter

Want to keep up-to-date on news and information?

Company

Newsletter

Want to keep up-to-date on news and information?

©2023. All rights reserved. Terms & Privacy | Privacy Policy

Scroll to top